These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22289817)

  • 1. [Mix-up of Fc receptors in the response to monoclonal antibodies].
    Teillaud JL
    Med Sci (Paris); 2012 Jan; 28(1):11-3. PubMed ID: 22289817
    [No Abstract]   [Full Text] [Related]  

  • 2. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunology. The adjuvant effects of antibodies.
    Smyth MJ; Kershaw MH
    Science; 2011 Aug; 333(6045):944-5. PubMed ID: 21852479
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
    Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
    Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
    Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J; Brück J; Lenz J; Knop J; Tüting T
    Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted cellular immunotherapy with bifunctional antibodies.
    Nelson H
    Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
    Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
    Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunology. An antibody paradox, resolved.
    Prlic M; Bevan MJ
    Science; 2006 Mar; 311(5769):1875-6. PubMed ID: 16574856
    [No Abstract]   [Full Text] [Related]  

  • 14. [Monoclonal antibodies: therapeutic possibilities and limitations].
    Tax WJ; Capel PJ; Koene RA
    Tijdschr Kindergeneeskd; 1987 Feb; 55(1):1-9. PubMed ID: 3551184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy.
    Banz A; Cremel M; Rembert A; Godfrin Y
    Vaccine; 2010 Apr; 28(17):2965-72. PubMed ID: 20188177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of agonistic anti-CD40 therapy in treatments for cancer.
    Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
    Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.
    Nisticò P; Mortarini R; De Monte LB; Mazzocchi A; Mariani M; Malavasi F; Parmiani G; Natali PG; Anichini A
    J Clin Invest; 1992 Sep; 90(3):1093-9. PubMed ID: 1387883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
    Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.